A 73-year-old veteran experienced a resolution of hypersexual behavior and auditory hallucinations after transitioning to a paliperidone long-acting injectable (LAI), according to a report in Medscape.
The patient, who had long-standing schizophrenia, initially failed to respond to lurasidone and sertraline.
The veteran’s hypersexuality and hyperreligiosity persisted despite these oral medications, eventually leading to an incident of sexual misconduct. His treatment team shifted his regimen to oral risperidone before moving to the paliperidone LAI, which addresses neurochemical pathways involving dopamine D2 and serotonin 2A receptors.
Following the initiation of the long-acting injectable, the patient showed significant improvement in his overall mood. Medscape reported that his alcohol consumption and hypersexual behaviors decreased while his renal and hepatic functions remained stable.
The patient underwent six months of individual psychotherapy alongside the medication. By the end of this period, his auditory hallucinations had resolved and his psychosocial functioning had improved.
The case highlights the potential for LAI antipsychotics to manage comorbid impulsive behaviors in patients with schizophrenia. Because the neurochemical pathways targeted by paliperidone are linked to impulse control, the results suggest a broader application for this class of medication.
The report emphasizes that treating schizophrenia with comorbid hypersexuality remains a complex clinical challenge. Ongoing monitoring and individualized treatment strategies are essential to ensure patient stability and psychosocial health.
How does paliperidone affect impulse control?
Paliperidone acts as an antagonist of dopamine D2 and serotonin 2A receptors. These specific neurochemical pathways are known to play a role in the regulation of impulse control.
What was the primary treatment shift for this patient?
The patient moved from oral lurasidone and sertraline to oral risperidone, and finally to a paliperidone long-acting injectable, which resulted in the stabilization of his symptoms.
Is long-term monitoring required for this treatment?
Yes, the report notes that ongoing monitoring and individualized treatment plans remain necessary for patients with schizophrenia and comorbid hypersexual behaviors.
Keep reading